Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Pittsburgh, Nov. 08, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at the Lotte New York Palace Hotel.
Mr. Moch’s presentation will include a corporate update as well as summary of results from the company’s Phase 1b/2a study of CT1812 in patients with mild-to-moderate Alzheimer’s disease. These results, which were recently presented at the annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, showed that CT1812 was well tolerated and generated a differential change compared to placebo in the levels of several key cerebrospinal fluid proteins that are dysregulated in Alzheimer’s disease.
About CT1812
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Aβ) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Study COG0102 was supported in part under Award Number RF1AG054176 from The National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.
Cognition Therapeutics [email protected] 412-465-0095 Aline Sherwood Scienta Communications [email protected] 312-238-8957
